A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 382 participants.
Also called NCT03337308
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 382 participants
- Sponsor
- Registry
-
NCT03337308
-
- Other papers using this trial's data
- Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03337308. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-23 (actual); primary completion 2018-06-18 (actual). Results posted on 2020-04-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
- Condition
- Hyperlipidemias
- Intervention (Combination product)
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination
- Intervention (Drug)
- Bempedoic Acid
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Placebos
- Lead sponsor
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03337308- Content hash
3bd36f6fc87c0577bcd1ede0967444cf11d77f2c57bae234f0c1bde1973215c3